Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Bexsero

- PMLiVE

ViiV submits dolutegravir for approval to treat HIV in US, EU and Canada

GSK-Pfizer joint venture takes next step towards commercialisation

- PMLiVE

Year-end FDA approvals for Novartis, GSK drugs

Agency gives go-ahead to Cushing’s disease treatment Signifor and raxibacumab for inhalational anthrax

- PMLiVE

GSK’s four-strain flu vaccine debuts in the US

Fluarix Quadrivalent protects against two influenza A and two influenza B subtypes

GSK teams up with Vodafone for mHealth initiative

Aims to use mobile technology to improve childhood vaccination rates in Mozambique

- PMLiVE

GSK raises stake in Nigerian unit

Set to expand in growing market

- PMLiVE

GSK consumer puts six-figure Day+Night Nurse campaign with Time Out London

Day+Night Nurse brand gets multi-media push with Time Out campaign developed by Grey London and MediaCom

- PMLiVE

Ligand/GSK’s Promacta cleared for hep C in US

New FDA approval is expected to open up a significant new market for the drug

Novartis building

CHMP backs Novartis’ Bexsero, Exjade

European recommendations for meningitis vaccine and thalassaemia treatment

- PMLiVE

Pharma’s growing ease with social media

GSK's participation last week in a Twitter chat is a sign of how comfortable the industry has become with social media

- PMLiVE

GSK’s malaria vaccine effects ‘modest’ in infants

Less than expected efficacy findings surprise researchers

- PMLiVE

UK to use GSK’s Rotarix in rotavirus vaccination programme

Chosen ahead of Merck & Co’s RotaTeq

- PMLiVE

GSK and XenoPort end restless legs syndrome collaboration

Follows tough approval period for Horizant and subsequent poor sales 

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links